Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor and thiazolidinedione FDC in type 2 diabetes mellitus
NCT07057479Phase 3Withdrawn
- Sponsor
- Eurofarma
- Start
- Sep 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eurofarma. Primary endpoint: Change in glycated hemoglobin at 24 weeks. Planned start Sep 2026; status: withdrawn.
02
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07057479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057479.